ANTONY, France, and EPALINGES, Switzerland, October 17th, 2019 - Stallergenes Greer, a worldwide leader in Allergen Immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development based on Contiguous Overlapping Peptides (COP), today announced the start of a new research study to evaluate the effects of second-generation COP allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.
This research collaboration combines the longstanding know-how of Stallergenes Greer in AIT with the ultra-fast AIT approach developed by Anergis and its partner Mymetics, namely the second-generation of COP allergen immunotherapy based on Anergis COPs and Mymetics virosomes (COP-Virosomes).
In 2018, Anergis and Mymetics reported that the COP-Virosomes were able to elicit a strong boost in TH1 antibody response without any IgE response. Stallergenes Greer will now test COP-Virosomes in an in-house therapeutic model of birch pollen allergy. This model has been shown as having predictive value towards the clinical efficacy for AIT candidates.

Press release